Literature DB >> 10861275

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

F Degos1, C Christidis, N Ganne-Carrie, J P Farmachidi, C Degott, C Guettier, J C Trinchet, M Beaugrand, S Chevret.   

Abstract

BACKGROUND: In patients with hepatitis C virus (HCV) infection and cirrhosis, long term outcome and the incidence of hepatocellular carcinoma (HCC) are still debated.
DESIGN: From January 1987 to January 1997, 416 patients (240 male, median age 57 years) with uncomplicated Child-Pugh A HCV related cirrhosis were followed in two Paris area centres from diagnosis of cirrhosis until death or reference date (1 June 1998). The analysis used a three state disability model generalising the Cox model.
RESULTS: Of the 416 patients, 60 developed HCC with a five year rate of 13.4% (95% confidence interval (CI) 9.0-17.8%) and 83 died (including 34 with HCC), with a five year death rate of 15.3% (95% CI 12.6-18.0%). By multivariable analysis, time to HCC relied on age (hazard ratio (HR) 1.05 per year; p=0.0005), male sex (HR 2.13; p=0.01), oesophageal varices (HR 2.36; p= 0.008), decreased platelet count (HR 0.99; p=0. 03), and bilirubin level (HR 1.01; p=0.003), while death after HCC was mainly related to tobacco consumption (HR 1.04; p=0.0006). In contrast, death free of HCC was dependent on age (HR 1.04; p=0.01), oesophageal varices (HR 2.75; p=0.001), low platelet count (HR 0.99; p=0.006), and albumin level (HR 0.90; p=0.0001).
CONCLUSION: The incidence of HCC and mortality should be higher in these patients than previously stated, and prognostic factors of HCC and death are closely related age and symptoms of portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861275      PMCID: PMC1727946          DOI: 10.1136/gut.47.1.131

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).

Authors:  G Fattovich; G Giustina; F Degos; G Diodati; F Tremolada; F Nevens; P Almasio; A Solinas; J T Brouwer; H Thomas; G Realdi; R Corrocher; S W Schalm
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

2.  Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus.

Authors:  F Roudot-Thoraval; A Bastie; J M Pawlotsky; D Dhumeaux
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

3.  Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study.

Authors:  S Bruno; E Silini; A Crosignani; F Borzio; G Leandro; F Bono; M Asti; S Rossi; A Larghi; A Cerino; M Podda; M U Mondelli
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

4.  Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

Authors:  G Mazzella; E Accogli; S Sottili; D Festi; M Orsini; A Salzetta; V Novelli; A Cipolla; C Fabbri; A Pezzoli; E Roda
Journal:  J Hepatol       Date:  1996-02       Impact factor: 25.083

5.  Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

Authors:  A Kasahara; N Hayashi; K Mochizuki; M Takayanagi; K Yoshioka; S Kakumu; A Iijima; A Urushihara; K Kiyosawa; M Okuda; K Hino; K Okita
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

6.  Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis.

Authors:  N V Naoumov; S Chokshi; E Metivier; G Maertens; P J Johnson; R Williams
Journal:  J Hepatol       Date:  1997-08       Impact factor: 25.083

7.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

Authors:  G Fattovich; G Giustina; F Degos; F Tremolada; G Diodati; P Almasio; F Nevens; A Solinas; D Mura; J T Brouwer; H Thomas; C Njapoum; C Casarin; P Bonetti; P Fuschi; J Basho; A Tocco; A Bhalla; R Galassini; F Noventa; S W Schalm; G Realdi
Journal:  Gastroenterology       Date:  1997-02       Impact factor: 22.682

Review 8.  Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma.

Authors:  W H Caselmann; M Alt
Journal:  J Hepatol       Date:  1996       Impact factor: 25.083

9.  Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis.

Authors:  N Ganne-Carrié; C Chastang; F Chapel; C Munz; D Pateron; M Sibony; P Dény; J C Trinchet; P Callard; C Guettier; M Beaugrand
Journal:  Hepatology       Date:  1996-05       Impact factor: 17.425

10.  Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors:  S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

View more
  85 in total

1.  Interferon therapy reduces the risk for hepatocellular carcinoma.

Authors:  J L Brown
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

2.  Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B.

Authors:  Do Young Kim; Seung Up Kim; Sang Hoon Ahn; Jun Yong Park; Jung Min Lee; Young Nyun Park; Ki Tae Yoon; Yong Han Paik; Kwan Sik Lee; Chae Yoon Chon; Kwang-Hyub Han
Journal:  Dig Dis Sci       Date:  2008-11-13       Impact factor: 3.199

3.  Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series.

Authors:  Robert J Wong; Robert Gish; Todd Frederick; Natalie Bzowej; Catherine Frenette
Journal:  Dig Dis Sci       Date:  2010-11-03       Impact factor: 3.199

4.  Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma.

Authors:  Philippe Couvert; Alain Carrié; Jacques Pariès; Jenny Vaysse; Audrey Miroglio; Antoine Kerjean; Pierre Nahon; Jamel Chelly; Jean-Claude Trinchet; Michel Beaugrand; Nathalie Ganne-Carrié
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

5.  Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases.

Authors:  Noriyuki Obara; Yoshiyuki Ueno; Koji Fukushima; Yu Nakagome; Eiji Kakazu; Osamu Kimura; Yuta Wakui; Osamu Kido; Masashi Ninomiya; Takayuki Kogure; Jun Inoue; Yasuteru Kondo; Masaaki Shiina; Takao Iwasaki; Takeshi Yamamoto; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

6.  Comparison of liver biopsy and transient elastography based on clinical relevance.

Authors:  Ryota Masuzaki; Ryosuke Tateishi; Haruhiko Yoshida; Erik Goto; Takahisa Sato; Takamasa Ohki; Tadashi Goto; Hideo Yoshida; Fumihiko Kanai; Yosuke Sugioka; Hitoshi Ikeda; Shuichiro Shiina; Takao Kawabe; Masao Omata
Journal:  Can J Gastroenterol       Date:  2008-09       Impact factor: 3.522

7.  Prognostic index of cirrhotic patients with hepatic encephalopathy with and without hepatocellular carcinoma.

Authors:  Keiichiro Yoneyama; Yuka Nebashi; Yuji Kiuchi; Minoru Shibata; Keiji Mitamura
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 8.  Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.

Authors:  Cristina Della Corte; Alessio Aghemo; Massimo Colombo
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

9.  Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection.

Authors:  Mayumi Tokunaga; Hirofumi Uto; Kohei Oda; Masahito Tokunaga; Seiichi Mawatari; Kotaro Kumagai; Kouichi Haraguchi; Makoto Oketani; Akio Ido; Nobuhito Ohnou; Atae Utsunomiya; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2014-01-25       Impact factor: 7.527

Review 10.  Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.

Authors:  Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.